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Abstract
Purpose Women who receive chemotherapy for a first
primary breast cancer have been observed to have a
reduced risk of contralateral breast cancer (CBC), however,
whether the genetic profile of a patient modifies this pro-
tective effect is currently not understood. The purpose of
this study is to investigate the impact of germline genetic
variation in genes coding for drug metabolizing enzymes,
transporters, and targets on the association between che-
motherapy and risk of CBC.
Methods From the population-based Women’s Environ-
ment Cancer and Radiation Epidemiology (WECARE)
Study, we included 636 Caucasian women with CBC
(cases) and 1,224 women with unilateral breast cancer
(controls). The association between common chemothera-
peutic regimens, CMF and FAC/FEC, and risk of CBC
stratified by genotype of 180 single nucleotide polymor-
phisms in 14 genes selected for their known involvement in
metabolism, action, and transport of breast cancer chemo-
therapeutic agents, were determined using conditional
logistic regression.
Results CMF (RR = 0.5, 95 % CI 0.4, 0.7) and FAC/FEC
(RR = 0.7, 95 % CI 0.4, 1.0) are associated with lower
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CBC risk relative to no chemotherapy in multivariable-
adjusted models. Here we show that genotype of selected
genes involved in the metabolism and uptake of these
therapeutic agents does not significantly alter the protective
effect of either CMF or FAC/FEC on risk of CBC.
Conclusion The results of this study show that germline
genetic variation in selected gene does not significantly
alter the protective effect of CMF, FAC, and FEC on risk
of CBC.
Keywords Genetic variation  Chemotherapy  CMF 
Contralateral breast cancer
Background
Adjuvant chemotherapy is indicated in the clinical man-
agement of most premenopausal women and postmeno-
pausal women with ER- tumors, improving disease-free and
overall survival [1–5]. Studies have also shown that the risk
of asynchronous contralateral breast cancer (CBC) is lower
among individuals who receive chemotherapy for treatment
of their first primary breast cancer [6, 7], with overall CBC
risk reductions of 30–80 % reported in observational stud-
ies of women treated for breast cancer [7–12].
Germline genetic variation in drug metabolizing
enzymes and transporters is thought to contribute to the
observed inter-individual variation in treatment efficacy
[13, 14]. The extent to which variation in these genes
modifies the association between chemotherapy and risk of
CBC is not known. Candidate genes can be classified into
three main categories: phase I enzymes [e.g., cytochrome
P450 (CYP) enzymes], phase II conjugation enzymes [e.g.,
glutathione S-transferases (GSTs)], and drug transporters
(e.g., ABCB1). Together, these proteins influence the bio-
activation, inactivation, and detoxification of a wide range
of therapeutics [13]. The impact of variation in these genes
on the association between chemotherapy and risk of CBC
is not known.
In this study, we examined the impact of common single
nucleotide variation in genes coding for drug metabolizing
enzymes (CYP1A1, CYP1B1, CYP2A6, CYP2B6, CYP2C9,
CYP2D6, CYP3A4, CYP3A5, GSTM1, GSTM2, GSTP1),
targets (DHFR, MTHFR), and transporters (ABCB1),
known to be involved in the metabolism and action of
drugs commonly used in polychemotherapy regimens for
breast cancer (e.g., cyclophosphamide, anthracyclines, and
antimetabolites) [14, 15], on risk of CBC in the Women’s
Environment Cancer and Radiation Epidemiology (WE-
CARE) Study, a population-based case–control study of




Participants were identified through five population-based
cancer registries: Los Angeles County Cancer Surveillance
Program; Cancer Surveillance System of the Fred Hutch-
inson Cancer Research Center (Seattle); State Health Reg-
istry of Iowa; and the Cancer Surveillance Program of
Orange County/San Diego-Imperial Organization for Can-
cer Control (Orange County/San Diego). These cancer
registries contribute to the National Cancer Institute Sur-
veillance, Epidemiology, and End Results (SEER) program.
The fifth registry from which subjects were recruited was the
Danish Breast Cancer Cooperative Group Registry, sup-
plemented by data from the Danish Cancer Registry [16].
Details of CBC case and UBC control eligibility have
been described previously [16]. Briefly, cases were women
diagnosed prior to age 55 years, from 1985 to 2000, with
invasive breast cancer that had not spread beyond regional
lymph nodes. This had to be followed by a second in situ or
invasive breast cancer diagnosed in the contralateral breast
at least 1 year later. The ‘at-risk’ interval was defined as
starting at the time of first breast cancer diagnosis and
ending at reference date, that is, date of the second breast
cancer diagnosis in cases (reference date) or the corre-
sponding date in matched controls. Two controls were
individually matched to each case on year of birth (in
5-year strata), year of diagnosis (in 4-year strata), registry
region, and race/ethnicity. All women had to be alive at the
time of contact and able to complete a telephone interview
and donate a blood sample. Counter-matching based on
registry-reported radiation treatment status was used to
improve the statistical efficiency of the study design. Thus,
for each radiation exposed case, one radiation exposed
control and one unexposed control were selected from the
relevant stratum; and for each unexposed case, two radia-
tion exposed controls were selected [16].
Across the five cancer registries, 708 cases and 1,399
controls completed the study interview and provided a blood
sample. Four individuals were excluded from the current
analysis because they did not consent to genotyping beyond
the initial ATM, BRCA1, and BRCA2 mutation screening. To
minimize the potential influence of ancestral differences in
genotype frequencies, all analyses were restricted to Cauca-
sian women (n = 1,933) as recorded by the cancer registry.
Further exclusions were made after genotyping (see below).
Data collection
The data collection protocol was approved by the institu-
tional review board at each of the participating centers and
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by the Ethical Committee System in Denmark. Each
woman provided written informed consent. Details of the
study questionnaire have been published previously and
included questions about known breast cancer risk factors
[16]. Medical records, pathology reports, and hospital
charts, in addition to self-reported data (collected during
the telephone interview), were used to collect detailed
treatment information (surgery, chemotherapy, hormonal
therapy, radiation therapy) on the first primary breast
cancer as well as during the at-risk period. Information
collected on chemotherapy and hormonal therapy included
dates of administration, reason for treatment (e.g., primary
disease, recurrence), and type of drug. The most common
chemotherapeutic regimens received by women in the
WECARE Study population were cyclophosphamide
(CTX), methotrexate (MTX), 5-fluorouracil (5FU) (CMF)
(63 % of women treated with chemotherapy were treated
with CMF) and 5FU, doxorubicin (Adriamycin), CTX
(FAC) or 5FU, epirubicin, CTX (FEC) (19 % of women
treated with chemotherapy were treated with FAC/FEC)
(Table 1). All other drug combinations were coded as
‘other’ chemotherapy. For the current analyses, a woman
was classified as having received CMF or FAC/FEC if she
received these combinations of drugs any time during her
treatment for a first primary breast cancer and prior to the
reference date.
Genotyping
Genes were selected for their known involvement in the
metabolism, action, and transport of chemotherapeutic
agents commonly used to treat breast cancer. A list of
genes and their associated drugs can be found in Table 2.
DNA was prepared from blood samples by red cell lysis
and standard methods of phenol/chloroform extraction.
Samples were genotyped with Illumina’s HumanOmni1-
Quad BeadChip (Illumina Inc., San Diego, CA, USA) as
part of the WECARE Study’s GWAS effort. Default
Omni1-Quad cluster definitions supplied by Illumina were
used to call genotypes, and single nucleotide polymor-
phisms (SNPs) with GenTrain scores \0.36 were consid-
ered ‘no calls,’ and samples with call rates \95 % were
excluded in addition to other exclusion criteria described
below. Each 96 well plate included one inter-plate positive
quality control sample (NA06990—Coriell Cell Reposito-
ries). In addition, 38 blinded and 46 unblinded quality
controls replicates from the study sample were genotyped.
Concordance rates for both the Coriell and study sample
replicates were high: [99.99 %.
Additional genotyping in these genes was performed to
broaden gene coverage. SNP lists from the HapMap project
(http://hapmap.ncbi.nlm.nih.gov/) were imported into
Tagger (in Haploview) [17], and haplotype tagging SNPs
(tagSNPs) were selected based on patterns of linkage dis-
equilibrium (LD) with boundaries suggested by Gabriel
et al. [18]. tagSNPs were selected based on pairwise tag-
ging with a minimum r2 of 0.90. Multiplex SNP genotyp-
ing was carried out using the Illumina Golden GateTM
assay on custom BeadChips (Illumina Inc., San Diego, CA,
USA). Laboratory methods and sample control measures
have been described previously [19].
The CYP2D6*4 (rs3892097) variant was genotyped by a
modified MGB Eclipse probe assay (Epoch Biosciences,
ELITech Group, Paris, France). The outer primers designed
to exclude pseudogenes were 50 AGCCTGCCCCAGCCA
AGGGAGC 30 and 50 CTCGGTCTCTCGCTCCGCAC 30.
The internal primers were designed by Epoch Biosciences
to encompass the SNP: 50 AATAAATCATAACCCCTTA
CCCGCATCTC 30 and 50 GATCACGTTGCTCACGGCT
TTGTCCAAGAG 30. DNA was amplified using the stan-
dard Eclipse protocol except that in the first 15 of 50
cycles, and the annealing temperature was increased by ten
degrees to 68 C. This method resulted in 100 % concor-
dance of genotypes among the 24 % blinded, re-sampled
DNAs. A subset of samples (17 %) was confirmed by a
second method, allele-specific tetra-primer PCR, and sep-
aration of the allele-specific fragment sizes on 1 % agarose
[20].
Quality control steps applied to the genome-wide asso-
ciation study (GWAS) data lead to further subject exclu-
sions: (a) Women with SNP call rates \95 % were
excluded (n = 22); (b) Population stratification was
investigated using EIGENSTRAT [21]; using the first two
principal components, 9 outliers with significant African or
Chinese ancestry were identified for exclusion; and (c) 14
additional participants were excluded due to incomplete
matched sets. Identity by descent was examined using
PLINK [22] identifying 3 pairs of sisters, including one
pair of identical twins. These women were not excluded
from the analysis. An additional 28 subjects were excluded
because they had [5 % missing genotypes on the SNP
BeadChips. Analyses are based on the remaining 1,860
participants (636 CBC cases and 1,224 UBC controls) with
genotype data from both the Omni1-Quad and custom bead
chips platforms.
Within the selected genes of interest, 260 SNPs were
genotyped on the OMNI platform, 27 SNPs on the SNP
BeadChip, and rs3892097 (CYP2D6*4) on a modified
MGB Eclipse probe assay (for a total of 287 genotyped
SNPs). SNPs with[10 % missing (n = 16) and those that
were monomorphic (n = 87) were excluded. Although
Hardy–Weinberg equilibrium may not strictly apply since
all participants in the study were affected with breast
cancer, 4 SNPs deviating from Hardy–Weinberg equilib-
rium (p \ 0.001) were also excluded. This left 180 SNPs in
or near 14 genes to be included in the analyses: 1 SNP in
Cancer Causes Control (2013) 24:1605–1614 1607
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Table 1 Characteristics of selected cases (women with asynchronous CBC) and controls (women with UBC only) from the WECARE Study
population
Variable Median (range) Cases (CBC) Controls (UBC)
Median (range) Median (range)
Age at first diagnosis (years) 46 (23–55) 46 (24–55) 46 (23–55)
Age at reference date (years) 51 (27–71) 51 (27–71) 51 (27–69)
Length of at-risk period (years)a 4 (1–16) 4 (1–16) 4 (1–16)
Variable Level Cases (CBC) Controls (UBC)
n % n %
Study site Iowa 107 17 206 17
Orange and San Diego Counties 105 17 202 17
Los Angeles 154 24 290 24
Seattle 94 15 187 15
Denmark 176 28 339 28
Year of first diagnosis 1985–1988 221 35 422 35
1989–1992 214 34 414 34
1993–1996 160 25 309 25
1997? 41 6 79 6
Chemotherapy No 355 56 562 46
Yes 281 44 662 54
CMF Yes 155 24 439 36
FAC/FEC Yes 61 10 119 10
Tamoxifen treatment No 485 76 861 70
Yes 139 22 338 28
Unknown 12 2 25 2
Radiation treatment Never 322 51 240 20
Ever 314 49 984 80
Histology of first breast cancer Lobular 82 13 120 10
Other 554 87 1,104 90
Stage of first breast cancer Localized 456 72 793 65
Regional 180 28 431 35
ER Status of first breast cancerb Positive 302 47 656 54
Negative 165 26 288 24
Other 169 27 280 23
PR Status of first breast cancerb Positive 252 40 536 44
Negative 144 23 270 22
Other 240 38 418 34
Menopausal status/age at menopause at first diagnosis Premenopausal 468 74 919 75
Postmenopausal age \45 84 13 183 15
Postmenopausal age C45 83 13 118 10
Unknown 1 0.2 4 0
Family history of breast cancer None 420 66 954 78
C1 First-degree relative 205 32 246 20
Adopted 11 2 24 2
Includes Caucasian women with SNP call rates C95 %, without significant African or Asian ancestry with complete information on tamoxifen
treatment and genotype data from both the Omni1-Quad and custom BeadChip platforms (636 CBC cases and 1,224 UBC controls)
CBC = asynchronous contralateral breast cancer; UBC = unilateral breast cancer; CMF = cyclophosphamide, methotrexate, 5-fluorouracil; FAC/
FEC = cyclophosphamide, doxorubicin/epirubicin, 5-fluorouracil chemotherapy; ER = estrogen receptor, PR = progesterone receptor
a Beginning 1 year after first diagnosis extending to the reference date (date of second diagnosis in cases)
b Refers to receptor status of the first primary breast cancer. The ‘other’ category consists of women for whom no lab test was given, the test was
given and the results are unknown or the test was given and the results were borderline
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CYP1A1, 4 in CYP1B1, 2 in CYP2A6, 6 in CYP2B6, 4 in
CYP2C9, 9 in CYP2D6, 26 in CYP3A4, 33 in CYP3A5, 13
in DHFR, 3 in GSTM1, 1 in GSTM2, 22 in GSTP1, 54 in
MTHFR, and 2 in ABCB1 (Online Resource 1).
Statistical analysis
In analyses examining the impact of genotype on the
association between CMF and risk of CBC, the chemo-
therapy regimen variable was coded as CMF, other che-
motherapy regimens, and no chemotherapy. Similar coding
was used for FAC/FEC analyses. In all instances, the
comparison group was women who did not receive che-
motherapy. In the CMF analyses, FAC/FEC was coded as
‘other chemotherapy’ and vice versa. SNPs in genes that
code for enzymes involved in the metabolism or action of
cyclophosphamide, methotrexate, 5-fluorouracil, or doxo-
rubicin/epirubicin were included in the analyses (Table 2).
Based on the combination of drugs used in either regimen,
the same SNPs were included in the CMF and FAC/FEC
analyses.
Rate ratios (RR) and 95 % confidence intervals (CI)
were estimated using conditional logistic regression to
examine the association between chemotherapeutic regi-
men (CMF or FAC/FEC) and risk of CBC, stratified by
genotype for each SNP using the dominant model [0
(homozygous wild-type), 1 (heterozygous and homozygous
variant)]. Models were run adjusting for age at first breast
cancer diagnosis and included an ‘offset term’ (i.e., log
weight ‘covariate’ in the model where the coefficient of
this log weight is fixed at one [16]), taking into account the
sampling probabilities of the counter-matching. Multi-
variable adjusted models were also run including adjust-
ment for age at first diagnosis, family history, stage and
histology of first primary breast cancer, and other treat-
ments (hormonal therapy and radiation therapy). The
likelihood ratio test was used to test for heterogeneity of
treatment effect across genotypes.
Age and multivariable-adjusted [as described above]
analyses were also conducted to confirm the association
between chemotherapy and CBC risk in the subgroup of
women included in the current analyses [1,860 (88 %) of
the 2,107 total number of women in the WECARE Study].
A conservative Bonferroni correction was used to
determine the multiple comparison cut-point (a = 0.0003,
obtained from (0.05/180 SNPs) at which results were
considered statistically significant. All analyses were con-
ducted using SAS 9.2 (SAS Institute Inc., Cary, NC, USA).
Figures were generated using Microsoft Excel 2007.
Results
Selected characteristics of the eligible WECARE Study
population are shown in Table 1. Cases and controls were
Table 2 Candidate genes coding for selected drug metabolizing
enzymes, targets, and transporters
Drugs Genes of interest




Methotrexate, 5-fluorouracil DHFR, MTHFR, ABCB1
Doxorubicin (adriamycin),
epirubicin
GSTM1, GSTM2, GSTP1, ABCB1
P=0.0003a
P=0.05a
Fig. 1 Log10 p value for
heterogeneity (multivariable-
adjusted models) of the
association between CMF
treatment regimen and risk of
CBC for 180 SNPs. aThe dashed
line shows the p value cut-off of
0.05 and the solid line the
Bonferroni-corrected p value
cut-off of 0.0003
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similar for all matching characteristics. In multivariable-
adjusted models, both CMF (RR = 0.5, 95 % CI 0.4, 0.7)
and FAC/FEC (RR = 0.7, 95 % CI 0.4, 1.0) are associated
with lower risk of CBC relative to no chemotherapy. In
stratified analyses using the dominant model, chemother-
apy was protective with respect to risk of CBC, regardless
of genotype. Figures 1 and 2 show the -log10(p for het-
erogeneity) for each SNP, grouped by chromosome, and for
CMF and FAC/FEC analyses, respectively. Results show-
ing the association between CMF and FAC/FEC treatments
and risk of CBC stratified by genotype for all SNPs did not
differ in age and multivariable adjusted models and can be
found in Online Resource 2 and Online Resource 3,
respectively. Findings from some commonly studied can-
didate SNPs are reported below.
In multivariable-adjusted models, the variants
rs1801133 and rs1801131 in MTHFR, known to be asso-
ciated with altered enzyme activity, did not significantly
modify the reduction in CBC risk seen with CMF
(RR = 0.5, 95 % CI 0.3, 0.8 in rs1801133 wild-type
compared to RR = 0.7, 95 % CI 0.4, 1.1 in women who
are heterozygous or homozygous for the rs1801133 variant,
p for heterogeneity =0.29, and RR = 0.8, 95 % CI 0.5, 1.3
in rs1801131 wild-type compared to RR = 0.4, 95 % CI
0.3, 0.7 in women who are heterozygous or homozygous
for the rs1801131 variant, p for heterogeneity =0.01).
Rs1695 in GSTP1 also did not significantly modify the
effect of chemotherapy on risk of CBC (RR = 0.5, 95 %
CI 0.3, 0.9 in rs1695 wild-type compared to RR = 0.7,
95 % CI 0.4, 1.0 in women who are heterozygous or
homozygous for the rs1695 variant, p for heterogeneity
=0.49 in women receiving CMF, and RR = 0.9, 95 % CI
0.5, 1.8 in rs1695 wild-type compared to RR = 0.6, 95 %
CI 0.3, 1.1 in women who are heterozygous or homozygous
for the rs1695 variant, p for heterogeneity =0.25 in women
receiving FAC/FEC).
Similarly, the association between chemotherapy and
risk of CBC did not differ when stratified by CYP3A4*1B
(rs2740574) genotype (RR = 0.6, 95 % CI 0.4, 0.9 in
rs2740574 wild-type compared to RR = 1.0, 95 % CI 0.4,
2.7 in women who are heterozygous or homozygous for the
rs2740574 variant, p for heterogeneity =0.22 in women
receiving CMF, and RR = 0.7, 95 % CI 0.4, 1.2 in
rs2740574 wild-type compared to RR = 0.7, 95 % CI 0.2,
2.6 in women who are heterozygous or homozygous for the
rs2740574 variant, p for heterogeneity =0.91 in women
receiving FAC/FEC).
Discussion
Chemotherapy reduces the risk of CBC [6–12]; however,
the impact of germline genetic variation in drug metabo-
lizing enzymes, targets, and transporters on this association
has not been investigated. Consistent with our prior pub-
lication [8], chemotherapy was associated with a lower risk
of CBC. Here, we show that variation in these selected
genes did not alter this protective effect of chemotherapy
on risk of CBC in a large, well-characterized study popu-
lation. This is the first study to specifically address the
association between genetic variants, chemotherapy, and
risk of CBC and to show that chemotherapy is protective
with respect to CBC risk, despite differences in the genetic
profiles of the genes investigated here.
CTX, a widely used nitrogen mustard alkylating agent,
is a component of both the CMF and FAC/FEC regimens
and the most common agent received by the WECARE
Study population. The pharmacokinetics of CTX are highly
P=0.0003a
P=0.05a
Fig. 2 Log10 p value for
heterogeneity (multivariable-
adjusted models) of the
association between FAC/FEC
treatment regimen and risk of
CBC for 180 SNPs. aThe dashed
line shows the p value cut-off of
0.05 and the solid line the
Bonferroni-corrected p value
cut-off of 0.0003
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variable (reviewed in [23]). CTX is administered as an
inactive pro-drug that requires metabolization by several
cytochrome P450 enzymes including CYP2B6 [24],
CYP2C9 [25], and CYP3A4 [26] with minor contributions
from CYP2A6, CYP2C8, and CYP2C19 (reviewed in
[27]), to its active metabolite 4-hydroxycyclophosphamide
(4OHCTX), which is further detoxified by the phase II
enzymes GSTs [28]. Patient characteristics, including
weight and age, influence treatment efficacy, but some
variation in clinical response may also be attributed to
germline genetic variation in these phase I and phase II
enzymes. Comparison between studies is complicated by
the inclusion of different SNPs in different genes. Prior
studies have shown that some variants in CYPs and GSTs
can alter the pharmacokinetics of CTX metabolism [27, 29,
30] and influence clinical response and toxicity of CTX-
based chemotherapies [31–38]. Other studies have found
no association between genetic variants in these genes and
CTX pharmacokinetics [39] or outcome [40]. Our study of
some of these same variants found that genotype did not
alter the association between CTX-based chemotherapies
and risk of CBC.
MTX and 5FU are antimetabolites that interfere with
cellular metabolism. MTX acts by inhibiting two enzymes:
dihydrofolate reductase (DHFR) and thymidylate synthase
(TS). 5FU, as an anti-folate metabolite, has several cyto-
toxic mechanisms [41]. MTHFR is a central regulatory
enzyme in folate metabolism and has known variants that
impact enzyme function (e.g., rs1801131, rs1801133).
These variants have been shown to alter methotrexate
toxicity (reviewed in [42]). Variation in MTHFR has also
been shown to increase sensitivity to 5FU and decrease
sensitivity to MTX in breast cancer cell lines [43], increase
risk of mortality after chemotherapy for breast cancer [44],
and reduce 5FU response in colorectal cancer [45–47]. Pare´
et al. [48] found no association between variation in
MTHFR and disease-free survival in breast cancer patients
who received CMF or FEC. Our study also found that
variants in MTHFR, including those known to influence
enzyme function, did not modify the effect of chemother-
apy on risk of CBC.
Anthracyclines [e.g., doxorubicin, epirubicin (the 40-
epimer of doxorubicin)] have multiple anti-cancer mecha-
nisms including DNA intercalation, generation of free-
radicals, and disruption of topoisomerase II-mediated DNA
repair [49]. Doxorubicin is metabolized in the liver by the
phase I enzymes aldoketoreductases and carbonyl reduc-
tases to an active metabolite, doxorubicinol which is then
detoxified by phase II GSTs. Gor et al. [36] examined the
impact of variation in CYP3A4, CYP3A5, CYP2B6,
CYP2D6, CYP2C9, GSTP1, GSTM1, and GSTT1 and found
that women carrying at least one CYP3A4*1B variant allele
(rs2740574) had significantly shorter disease-free survival
than wild-type women. The same variants were examined
by Yao et al. [40], and they were not able to reproduce this
association. Another study found that variants in CYP2B6
(rs192709 and rs3211371) were associated with an
increased risk of dose delay in women receiving AC
(doxorubicin, cyclophosphamide) chemotherapy. Other
SNPs in this same gene (rs8192709, rs3745274, rs2279343)
were associated with worse outcome [37]. Our study found
that variation in CYP2B6 did not modify the effect of
FAC/FEC on risk of CBC.
Doxorubicin and MTX are also substrates of P-glyco-
protein, an efflux transporter that is the product of the
ABCB1 [multi-drug resistance (MDR-1)] gene (reviewed in
[50, 51]). Lal et al. [52] found that SNPs in ABCB1
increased drug exposure by decreasing its clearance. Var-
iation in ABCB1 has also been associated with clinical
response and overall survival in women receiving doxo-
rubicin-based chemotherapy [53–55]. Studies examining
the impact of variation in GSTP1 have been mixed [56, 57].
The strengths of this study include the population-based
design, the large number of women with CBC, enabling the
examination of CBC as an outcome, and the extensive
review of patient medical records and questionnaire data,
to obtain detailed treatment information. A limitation of the
tagSNP approach used here is that it does not address the
impact of less common or rare variants (MAF \ 5 %),
SNPs not in LD with typed variants, insertions/deletions,
epigenetic modifications, and copy number variations, on
treatment response. Further, complete gene coverage was
not achieved for all genes, and in some cases, a candidate
SNP approach was used (e.g., CYP1A1). It is possible that
un-typed variants in these candidate genes and variation in
genes not included in the current analysis could modify the
effect of treatment on risk of CBC. A further limitation of
this study is that for variants with a low minor allele fre-
quency or modest effects on the association between che-
motherapy and risk of CBC, our power is reduced.
Conclusion
This is the first study to specifically address the impact of
germline genetic variation on the association between
chemotherapy and risk of CBC. The results of this study
suggest that chemotherapy (CMF and FAC/FEC) is asso-
ciated with a lower risk of CBC regardless of genetic
variation in selected genes that code for proteins involved
in the metabolism of these commonly used chemothera-
peutic agents.
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